Joydeep Ghosh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Joydeep Ghosh has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
Deepak Dabkara
Tata Med Ctr, Dept Med Oncol, 14 MAR E-W, Kolkata 700156, W Bengal, India
6 shared publicationsSandip Ganguly
Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
5 shared publications- Bivas Biswas
Department of Medical Oncology, Tata Medical Center, Kolkata, India
4 shared publications Arunava Roy
Tata Med Ctr, Dept Gynaecol Oncosurg, 14 MAR E-W, Kolkata 700156, W Bengal, India
3 shared publicationsBivas Biswas
Tata Med Ctr, Dept Med Oncol, 14 MAR E-W, Kolkata 700156, W Bengal, India
3 shared publicationsJaydip Bhaumik
Tata Med Ctr, Dept Gynaecol Oncosurg, 14 MAR E-W, Kolkata 700156, W Bengal, India
3 shared publications
Latest Publications
- 15 September 2025
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 78 (1) , 162-173
Current Trends in Neoadjuvant Chemotherapy in Sinonasal Malignancies: A Scoping Review
- 15 September 2025
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 78 (1) , 162-173
Current Trends in Neoadjuvant Chemotherapy in Sinonasal Malignancies: A Scoping Review
- 1 December 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 10 (10) , e2400216
Gemcitabine Cisplatin and Durvalumab Experience in Advanced Biliary Tract Cancers: A Real-World, Multicentric Data From India
PURPOSE: Biliary tract cancers (BTCs) are usually diagnosed in advanced stages, where treatment options are either palliative chemotherapy and/or best supportive care. The breakthrough results of the TOPAZ-1 trial demonstrated a 24% decrease in risk of death at 2 years with the addition of durvalumab to chemotherapy. MATERIALS AND METHODS: This was a multicenter retrospective cohort study conducted across 14 institutions in India. All the patients were diagnosed with advanced BTCs. The primary objective was to assess median overall survival (mOS) with the use of durvalumab in combination with chemotherapy backbone. The patient details, treatment details, laboratory results, and outcome parameters were recorded from the prospectively collected databases. RESULTS: A total of 148 patients were included with a median age of 57.5 years; 36 (24.3%) patients had borderline Eastern Cooperative Oncology Group performance status ≥2. The most common subtype was gall bladder cancer (GBC), seen in 94 patients (63.5%); 126 (85.1%) patients presented with de novo metastases. At a median follow-up of 6.8 months (95% CI, 5.9 to 7.8), the estimated mOS for the entire cohort was 12 months (95% CI, 7.8 to 16.3) and median progression-free survival was 8.2 months (95% CI, 7.1 to 9.4) with objective response achieved in 44 (29.7%) patients, and the estimated 2-year OS being 25%. Immune-related grade 3/4 adverse events were reported in 11 (7.4%) patients. In multivariate analysis, age P = .001) and standard dose of durvalumab ( P < .001) were found to have improved OS compared with age >60 years and low dose of durvalumab. CONCLUSION: To our knowledge, these real-world data provide the first evidence in Indian context of the efficacy and safety of durvalumab plus chemotherapy in patients with advanced/metastatic BTCs especially in GBC.
- 1 December 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 10 (10) , e2400216
Gemcitabine Cisplatin and Durvalumab Experience in Advanced Biliary Tract Cancers: A Real-World, Multicentric Data From India
PURPOSE: Biliary tract cancers (BTCs) are usually diagnosed in advanced stages, where treatment options are either palliative chemotherapy and/or best supportive care. The breakthrough results of the TOPAZ-1 trial demonstrated a 24% decrease in risk of death at 2 years with the addition of durvalumab to chemotherapy. MATERIALS AND METHODS: This was a multicenter retrospective cohort study conducted across 14 institutions in India. All the patients were diagnosed with advanced BTCs. The primary objective was to assess median overall survival (mOS) with the use of durvalumab in combination with chemotherapy backbone. The patient details, treatment details, laboratory results, and outcome parameters were recorded from the prospectively collected databases. RESULTS: A total of 148 patients were included with a median age of 57.5 years; 36 (24.3%) patients had borderline Eastern Cooperative Oncology Group performance status ≥2. The most common subtype was gall bladder cancer (GBC), seen in 94 patients (63.5%); 126 (85.1%) patients presented with de novo metastases. At a median follow-up of 6.8 months (95% CI, 5.9 to 7.8), the estimated mOS for the entire cohort was 12 months (95% CI, 7.8 to 16.3) and median progression-free survival was 8.2 months (95% CI, 7.1 to 9.4) with objective response achieved in 44 (29.7%) patients, and the estimated 2-year OS being 25%. Immune-related grade 3/4 adverse events were reported in 11 (7.4%) patients. In multivariate analysis, age P = .001) and standard dose of durvalumab ( P < .001) were found to have improved OS compared with age >60 years and low dose of durvalumab. CONCLUSION: To our knowledge, these real-world data provide the first evidence in Indian context of the efficacy and safety of durvalumab plus chemotherapy in patients with advanced/metastatic BTCs especially in GBC.
- Open Access
- 1 January 2024
- Published by Medknow in UroCancer Clinics of India
- Vol. 2 (1) , 14-16
Controversies in Management of Localized Prostate Cancer: Before and After Radical Local Therapy
Summary: The therapeutic world of prostate cancer has evolved a lot in the last decade. Initially, we have only androgen deprivation therapies, earlier generation androgen receptor pathway inhibitor (ARPI), and chemotherapy. Now, we have multiple other options, and also there are ample data in all the spaces of its management. However, some areas need discussion, as controversies exist. In this review, we would like to throw some light on such controversial real in dealing with the biochemical recurrence after radical local therapy (RLT) and neoadjuvant treatment before RLT. We envisage to clear the cloud as per the existing literature.
- 1 January 2024
- Published by Medknow in UroCancer Clinics of India
- Vol. 2 (1) , 14-16
Open AccessControversies in Management of Localized Prostate Cancer: Before and After Radical Local Therapy
Summary: The therapeutic world of prostate cancer has evolved a lot in the last decade. Initially, we have only androgen deprivation therapies, earlier generation androgen receptor pathway inhibitor (ARPI), and chemotherapy. Now, we have multiple other options, and also there are ample data in all the spaces of its management. However, some areas need discussion, as controversies exist. In this review, we would like to throw some light on such controversial real in dealing with the biochemical recurrence after radical local therapy (RLT) and neoadjuvant treatment before RLT. We envisage to clear the cloud as per the existing literature.
- Open Access
- 1 April 2023
- Published by Medknow in Cancer Research, Statistics, and Treatment
- Vol. 6 (2) , 232-234
Pathological complete response in breast cancer: Is it truly a surrogate for outcome?
- 1 April 2023
- Published by Medknow in Cancer Research, Statistics, and Treatment
- Vol. 6 (2) , 232-234
Open AccessPathological complete response in breast cancer: Is it truly a surrogate for outcome?
- Open Access
- 13 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32493
First-line Rucaparib Plus Bevacizumab Maintenance Completed One-Year in Germline BRCA1-Mutated Advanced Ovarian Cancer
The present case study showed the novel approach of Rucaparib and Bevacizumab as first-line maintenance therapy in germline BRCA 1 mutated advanced high-grade serous carcinoma of the ovary. A 56-year-old female with high-grade serous carcinoma of the ovary (ECOG PS1) was treated with carboplatin and paclitaxel in combination with Bevacizumab (CPB), followed by interval debulking surgery. Since the patient was germline BRCA 1 positive, after completion of adjuvant chemotherapy, she was kept on Rucaparib along with Bevacizumab. The patient achieved a complete response and has been leading a disease-free life for the past one year with maintenance therapy of Rucaparib + Bevacizumab, though the patient did experience a few adverse events, including one episode of grade 3 anaemia, occasional grade 3 asthenia, and grade 2 diarrhoea (CTCAE V-4) which was managed by gradual dose reduction of Rucaparib from 600 mg twice daily dose to 300mg twice daily dose. With dose alteration of rucaparib along with bevacizumab as maintenance, the patient continues to tolerate rucaparib and stay relapse-free from disease.
- 13 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32493
Open AccessFirst-line Rucaparib Plus Bevacizumab Maintenance Completed One-Year in Germline BRCA1-Mutated Advanced Ovarian Cancer
The present case study showed the novel approach of Rucaparib and Bevacizumab as first-line maintenance therapy in germline BRCA 1 mutated advanced high-grade serous carcinoma of the ovary. A 56-year-old female with high-grade serous carcinoma of the ovary (ECOG PS1) was treated with carboplatin and paclitaxel in combination with Bevacizumab (CPB), followed by interval debulking surgery. Since the patient was germline BRCA 1 positive, after completion of adjuvant chemotherapy, she was kept on Rucaparib along with Bevacizumab. The patient achieved a complete response and has been leading a disease-free life for the past one year with maintenance therapy of Rucaparib + Bevacizumab, though the patient did experience a few adverse events, including one episode of grade 3 anaemia, occasional grade 3 asthenia, and grade 2 diarrhoea (CTCAE V-4) which was managed by gradual dose reduction of Rucaparib from 600 mg twice daily dose to 300mg twice daily dose. With dose alteration of rucaparib along with bevacizumab as maintenance, the patient continues to tolerate rucaparib and stay relapse-free from disease.
- Open Access
- 17 June 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 8 (8) , e2200135
Are We Right on Target? Is Comprehensive Genomic Profiling Ready for Prime Time in Resource-Constrained Settings?
- 17 June 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 8 (8) , e2200135
Open AccessAre We Right on Target? Is Comprehensive Genomic Profiling Ready for Prime Time in Resource-Constrained Settings?
- Open Access
- 14 September 2021
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 15
Multidisciplinary management of ovarian germ cell tumours—a single institutional study from India
Multidisciplinary management of ovarian germ cell tumours—a single institutional study from India Sandip Ganguly1, Sumedha Gargy2, Archisman Basu1,
- 14 September 2021
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 15
Open AccessMultidisciplinary management of ovarian germ cell tumours—a single institutional study from India
Multidisciplinary management of ovarian germ cell tumours—a single institutional study from India Sandip Ganguly1, Sumedha Gargy2, Archisman Basu1,
- Open Access
- 1 September 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 7 (7) , 1374-1379
Outcome of COVID-19 in Solid Organ Malignancies: Experience From a Tertiary Cancer Center in Eastern India
PURPOSE The COVID-19 pandemic has imposed a unique challenge to oncology patients. Outcome data on COVID-19 in patients with cancer from the Indian subcontinent are scarce in the literature. We aimed to evaluate the outcome of patients with COVID-19 on active systemic anticancer therapy. MATERIALS AND METHODS This is a retrospective study of patients with solid organ malignancies undergoing systemic therapy with a diagnosis of COVID-19 between March 2020 and February 2021. COVID-19 was diagnosed if a reverse transcriptase polymerase chain reaction assay from oropharyngeal or nasopharyngeal swab was positive for severe acute respiratory syndrome coronavirus 2. The objectives were to evaluate the outcome of COVID-19 and factors predicting the outcome. RESULTS A total of 145 patients were included with a median age of 58 years (range, 20-81 years). Treatment was curative in 60 (42%) patients. Of all symptomatic cases (n = 88, 61%), 50 had mild, 27 had moderate and 19 had severe COVID-19-related symptoms as per WHO criteria. Fifty (34%) patients required hospitalization with a median duration of hospital stay of 12 days (range, 4-25 days); five patients required intensive care unit admission. The rest were treated with home isolation and did not require further hospitalization. Twenty-two (15%) patients died, and the risk of death was significantly associated with severity of symptoms (odds ratio, 91.3; 95% CI, 9.1 to 919.5, P= .0001) but not with any other clinical factors. Drug holiday was given to 63 (44%) patients with a median duration of 25 days (range, 7-88 days). The median duration to reverse transcriptase polymerase chain reaction-negative was 16 days (range, 7-62 days). CONCLUSION COVID-19-related death rate was 15% among patients with solid organ malignancies. The severity of the symptoms was related to mortality. The majority of patients with mild symptoms were treated at home isolation. (C) 2021 by American Society of Clinical Oncology
- 1 September 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 7 (7) , 1374-1379
Open AccessOutcome of COVID-19 in Solid Organ Malignancies: Experience From a Tertiary Cancer Center in Eastern India
PURPOSE The COVID-19 pandemic has imposed a unique challenge to oncology patients. Outcome data on COVID-19 in patients with cancer from the Indian subcontinent are scarce in the literature. We aimed to evaluate the outcome of patients with COVID-19 on active systemic anticancer therapy. MATERIALS AND METHODS This is a retrospective study of patients with solid organ malignancies undergoing systemic therapy with a diagnosis of COVID-19 between March 2020 and February 2021. COVID-19 was diagnosed if a reverse transcriptase polymerase chain reaction assay from oropharyngeal or nasopharyngeal swab was positive for severe acute respiratory syndrome coronavirus 2. The objectives were to evaluate the outcome of COVID-19 and factors predicting the outcome. RESULTS A total of 145 patients were included with a median age of 58 years (range, 20-81 years). Treatment was curative in 60 (42%) patients. Of all symptomatic cases (n = 88, 61%), 50 had mild, 27 had moderate and 19 had severe COVID-19-related symptoms as per WHO criteria. Fifty (34%) patients required hospitalization with a median duration of hospital stay of 12 days (range, 4-25 days); five patients required intensive care unit admission. The rest were treated with home isolation and did not require further hospitalization. Twenty-two (15%) patients died, and the risk of death was significantly associated with severity of symptoms (odds ratio, 91.3; 95% CI, 9.1 to 919.5, P= .0001) but not with any other clinical factors. Drug holiday was given to 63 (44%) patients with a median duration of 25 days (range, 7-88 days). The median duration to reverse transcriptase polymerase chain reaction-negative was 16 days (range, 7-62 days). CONCLUSION COVID-19-related death rate was 15% among patients with solid organ malignancies. The severity of the symptoms was related to mortality. The majority of patients with mild symptoms were treated at home isolation. (C) 2021 by American Society of Clinical Oncology